EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy

Martin S Maron, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Theodore P Abraham, Michael Arad, Nuno Cardim, Lubna Choudhury, Brian Claggett, Caroline J Coats, Hans-Dirk Düngen, Pablo Garcia-Pavia und 23 weitere

Journal of the American College of Cardiology · 2024

DOI: 10.1016/j.jacc.2024.09.003 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American College of Cardiology, 2024. Verfasst von Martin S Maron und 34 weiteren Autor:innen. Beteiligte Einrichtung: Lahey Hospital and Medical Center, Burlington, Massachusetts, USA. Electronic address: martin.maron@lahey.org. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cytokinetics Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has not been fully defined. OBJECTIVES: This responder analysis from the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM) trial characterizes the clinical impact of aficamten. METHODS: Patients who were symptomatic of oHCM were randomized to aficamten (n = 142) or placebo (n = 140) daily for 24 weeks. Outcomes assessed included the proportion of patients with complete hemodynamic response (rest and Valsalva gradient

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicHumansMaleFemaleMiddle AgedDouble-Blind MethodAgedTreatment OutcomeAdultExercise ToleranceSymptom BurdenBenzylaminesUracil

Stichwörter der Autor:innen

aficamtencardiac myosin inhibitorclinical trialhypertrophic cardiomyopathyobstructive hypertrophic cardiomyopathytherapy

Substanzen

MYK-461BenzylaminesUracil

Autor:innen und Institutionen

  • Lahey Hospital and Medical Center, Burlington, Massachusetts, USA. Electronic address: martin.maron@lahey.org.
  • Oregon Health and Science University, Portland, Oregon, USA.
  • University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute Kansas City, Kansas City, Missouri, USA.
  • Complexo Hospitalario Universitario A Coruña, INIBIC, CIBERCV-ISCIII, A Coruña, Spain.
  • University of California, San Francisco, San Francisco, California, USA.
  • Chaim Sheba Medical Center, Ramat-Gan and Tel Aviv University, Israel.

Förderung

  • Cytokinetics Inc

Zitieren

APA

Maron, M. S., Masri, A., Nassif, M. E., Barriales-Villa, R., Abraham, T. P., Arad, M., Cardim, N., Choudhury, L., Claggett, B., Coats, C. J., Düngen, H. D., Garcia-Pavia, P., Hagège, A. A., Januzzi, J. L., Kulac, I., Lee, M. M. Y., Lewis, G. D., Ma, C. S., Michels, M., …, & SEQUOIA-HCM Investigators (2024). Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2024.09.003

Vancouver

Maron MS, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Arad M, et al. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2024. doi:10.1016/j.jacc.2024.09.003

BibTeX
@article{Maron2024,
  author = {Maron, Martin S and Masri, Ahmad and Nassif, Michael E and Barriales-Villa, Roberto and Abraham, Theodore P and Arad, Michael and Cardim, Nuno and Choudhury, Lubna and Claggett, Brian and Coats, Caroline J and Düngen, Hans-Dirk and Garcia-Pavia, Pablo and Hagège, Albert A and Januzzi, James L and Kulac, Ian and Lee, Matthew M Y and Lewis, Gregory D and Ma, Chang-Sheng and Michels, Michelle and Oreziak, Artur and Owens, Anjali T and Spertus, John A and Solomon, Scott D and Tfelt-Hansen, Jacob and van Sinttruije, Marion and Veselka, Josef and Watkins, Hugh C and Jacoby, Daniel L and Heitner, Stephen B and Kupfer, Stuart and Malik, Fady I and Meng, Lisa and Wohltman, Amy and Olivotto, Iacopo and SEQUOIA-HCM Investigators, SEQUOIA-HCM Investigators},
  title = {Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy},
  journal = {Journal of the American College of Cardiology},
  year = {2024},
  doi = {10.1016/j.jacc.2024.09.003}
}
Kostenlos starten →